Sharon Pok

Sharon Pok

Auto-generated profile, based on publicly available information

Sharon Pok

Liver Research Group, ANU Medical School, Australian National University at The Canberra Hospital, Garran, ACT, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Jessie Qiaoyi LiangJessie Qiaoyi Liang
Jessie Qiaoyi Liang
NTNarcissus Teoh
Narcissus Teoh
LXLixia Xu
Lixia Xu
SPSharon Pok
Sharon Pok
XLXiangchun Li
Xiangchun Li
JYJun Yu
Jun Yu
The underlining mechanisms of dietary cholesterol and nonalcoholic steatohepatitis (NASH) in contributing to hepatocellular carcinoma (HCC) remain undefined. Here we demonstrated that high-fat-non-cholesterol-fed mice developed simple steatosis, whilst high-fat-high-cholesterol-fed mice developed NASH. Moreover, dietary cholesterol induced larger and more numerous NASH-HCCs than non-cholesterol-induced steatosis-HCCs in diethylnitrosamine-treated mice. NASH-HCCs displayed significantly more aberrant gene expression-enriched signaling pathways and more non-synonymous somatic mutations than steatosis-HCCs (335 ± 84/sample vs 43 ± 13/sample). Integrated genetic and expressional alterations in NASH-HCCs affected distinct genes pertinent to five pathways: calcium, insulin, cell adhesion, axon guidance and metabolism. Some of the novel aberrant gene expression, mutations and core oncogenic pathways identified in cholesterol-associated NASH-HCCs in mice were confirmed in human NASH-HCCs, which included metabolism-related genes (ALDH18A1, CAD, CHKA, POLD4, PSPH and SQLE) and recurrently mutated genes (RYR1, MTOR, SDK1, CACNA1H and RYR2). These findings add insights into the link of cholesterol to NASH and NASH-HCC and provide potential therapeutic targets.

1 January 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
HHHan Kiat Ho
Han Kiat Ho
SPSharon Pok
Sharon Pok
SSSylvia Streit
Sylvia Streit
JRJens E. Ruhe
Jens E. Ruhe
SHStefan Hart
Stefan Hart
AUAxel Ullrich
Axel Ullrich

28 February 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
JBJennifer Brockhausen
Jennifer Brockhausen
STSzun S. Tay
Szun S. Tay
CGCandice A. Grzelak
Candice A. Grzelak
PBPatrick Bertolino
Patrick Bertolino
DBDavid G. Bowen
David G. Bowen
GMGeoff McCaughan
Geoff McCaughan

1 December 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JRJens E. Ruhe
Jens E. Ruhe
SSSylvia Streit
Sylvia Streit
SHStefan Hart
Stefan Hart
CWChee-Hong Wong
Chee-Hong Wong
KSKatja Specht
Katja Specht
AUAxel Ullrich
Axel Ullrich
Protein tyrosine kinases (PTKs) play a critical role in the manifestation of cancer cell properties, and respective signaling mechanisms have been studied extensively on immortalized tumor cells. To characterize and analyze commonly used cancer cell lines with regard to variations in the primary structure of all expressed PTKs, we conducted a cDNA-based sequence analysis of the entire tyrosine kinase transcriptome of 254 established tumor cell lines. The profiles of cell line intrinsic PTK transcript alterations and the evaluation of 155 identified polymorphisms and 234 somatic mutations are made available in a database designated “Tykiva” (tyrosine kinome variant). Tissue distribution analysis and/or the localization within defined protein domains indicate functional relevance of several genetic alterations. The cysteine replacement of the highly conserved Y367 residue in fibroblast growth factor receptor 4 or the Q26X nonsense mutation in the tumor-suppressor kinase CSK are examples, and may contribute to cell line–specific signaling characteristics and tumor progression. Moreover, known variants, such as epidermal growth factor receptor G719S, that were shown to mediate anticancer drug sensitivity could be detected in other than the previously reported tumor types. Our data therefore provide extensive system information for the design and interpretation of cell line–based cancer research, and may stimulate further investigations into broader clinical applications of current cancer therapeutics. [Cancer Res 2007;67(23):11368–76]

1 July 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
AAArfianti Arfianti
Arfianti Arfianti
SPSharon Pok
Sharon Pok
VBVanessa Barn
Vanessa Barn
WHW. Geoffrey Haigh
W. Geoffrey Haigh
MYMatthew M. Yeh
Matthew M. Yeh
GFGeoffrey C. Farrell
Geoffrey C. Farrell

30 May 2016 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SPSharon Pok
Sharon Pok
VBVanessa A Barn
Vanessa A Barn
HWHeng Jian Wong
Heng Jian Wong
ABAnneke C. Blackburn
Anneke C. Blackburn
PBPhilip Board
Philip Board
NTNarci C. Teoh
Narci C. Teoh